Combined Use of 18F-FDG PET and Corticosteroid for Diagnosis of Deep-seated Primary Central Nervous System Lymphoma without Histopathological Confirmatio
Not Applicable
- Conditions
- Primary Central Nervous System Lymphoma
- Registration Number
- JPRN-UMIN000017401
- Lead Sponsor
- Department of Neurosurgery, Graduate School of Medicine, Hokkaido University
- Brief Summary
Combining 18F-FDG PET and corticosteroids administration is an important alternative method that may lead to the diagnosis of deep-seated PCNSLs in cases with intractable histopathological confirmations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
any cases which were not matched every inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic accuracy
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does corticosteroid-induced metabolic modulation enhance FDG PET accuracy for deep-seated PCNSL diagnosis?
What are the comparative diagnostic advantages of FDG PET plus corticosteroids versus histopathology in PCNSL?
Which molecular biomarkers correlate with FDG PET response in corticosteroid-treated PCNSL patients?
What adverse events are associated with corticosteroid use in PCNSL diagnostic protocols involving FDG PET?
Are there alternative imaging biomarkers or corticosteroid combinations for non-invasive PCNSL detection?